We found that PAAD patients with concomitant KRAS G12D and TP53 mutations indeed had even worse overall survival (OS) compared with other PAAD patients in both entire TCGA cohort (N=179) (median OS, 15.12 vs. 21.44 months; HR, 2.01; 95% CI, 1.19–3.39; P=0.0013) and stage I–II PAAD patients (N=167) of TCGA cohort (median OS, 15.12 vs. 20.84 months; HR, 1.88; 95% CI, 1.11–3.20; P=0.0048) (Supplementary Figs. S9A and B, Supplemental Digital Content 3, http://links.lww.com/JS9/A234). Here, KRAS is linked to pancreatic adenocarcinoma.